Latest Content

Patients with myasthenia gravis (MG) lived 15 to 19 years longer than those with multiple sclerosis (MS) across 4 datasets.

FDA approves rusfertide, a first-in-class hepcidin-mimetic for polycythemia vera, cutting phlebotomies and improving hematocrit control and QOL.

Traveling a greater distance for cataract surgery significantly lowered the odds of receiving it, with each 100 miles cutting odds by 14% overall.

China survey reveals what R/R mantle cell lymphoma patients and doctors value after BTK failure—overall survival tops trade-offs despite CRS risk.

A 3-cohort study finds CC16 levels flag airway remodeling and fibrosis-like lung damage up to 3 years after severe COVID-19.

Transplant weight-loss access, a new dermatomyositis drug, mifepristone safety views, and racial gaps in cataract surgery and CRC mortality.

This study links NT1 to anterior hypothalamus shrinkage, advancing orexin/hypocretin insights and a potential biomarker for narcolepsy with cataplexy.

DOJ policy shifts have put HHS on the same side as states seeking to narrow Section 504's disability integration mandate in Texas v Kennedy.

The phase 3 MINT trial found inebilizumab significantly reduced exacerbations and rescue therapy use in patients with generalized myasthenia gravis.